A phase 1 safety and immunogenicity study of the Pharmexa-Epimmune HIV-1 CTL epitope-based DNA vaccine (EP HIV-1090) administered using a Biojector 2000 needle free immunization device in HIV-1 infected individuals receiving potent combination antiretroviral therapy (ART)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2007
At a glance
- Drugs EP 1090 (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions
- Sponsors Epimmune
- 10 Jun 2017 Biomarkers information updated
- 17 Dec 2007 Status changed from recruiting to in progress. Updated from ClinicalTrials.gov.
- 31 Aug 2006 New trial record.